Anchor Investment Management LLC Sells 6,349 Shares of Pfizer Inc. $PFE

Anchor Investment Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 4.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 133,115 shares of the biopharmaceutical company’s stock after selling 6,349 shares during the quarter. Anchor Investment Management LLC’s holdings in Pfizer were worth $3,373,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Glenview Trust co grew its stake in shares of Pfizer by 17.4% in the first quarter. Glenview Trust co now owns 493,600 shares of the biopharmaceutical company’s stock worth $12,508,000 after acquiring an additional 73,070 shares during the last quarter. SageView Advisory Group LLC grew its stake in shares of Pfizer by 21.5% in the first quarter. SageView Advisory Group LLC now owns 57,382 shares of the biopharmaceutical company’s stock worth $1,454,000 after acquiring an additional 10,140 shares during the last quarter. Advisory Alpha LLC grew its stake in shares of Pfizer by 39.3% in the first quarter. Advisory Alpha LLC now owns 35,290 shares of the biopharmaceutical company’s stock worth $894,000 after acquiring an additional 9,963 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, SCS Capital Management LLC purchased a new stake in shares of Pfizer in the first quarter worth $778,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Performance

NYSE PFE opened at $24.74 on Wednesday. The stock has a market capitalization of $140.66 billion, a PE ratio of 13.16, a P/E/G ratio of 0.87 and a beta of 0.55. The business has a 50 day simple moving average of $24.85 and a two-hundred day simple moving average of $24.33. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.